Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 148

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 148
---
 the Institute of Chartered Accountants in England and Wales.

The financial statements as
of December 31, 2023, and for each of the two years in the period then ended, incorporated by reference into this prospectus and in the
registration statement, have been so incorporated in reliance on a report of Forvis Mazars LLP (then-named Mazars LLP), an independent
registered accounting firm, given on authority of said firm as experts in auditing and accounting. The report on the financial statements
for the year ended December 31, 2023 contains an explanatory paragraph in Note 2 regarding our ability to continue as a going concern.

Forvis Mazars LLP, London,
United Kingdom, is a member of the Institute of Chartered Accountants in England and Wales.

<div align='center'>WHERE YOU CAN FIND MORE INFORMATION</div>

We are subject to periodic
reporting and other informational requirements of the Exchange Act, as applicable to foreign private issuers. Accordingly, we are required
to file reports, including annual reports on Form 20-F, and other information with the SEC. As a foreign private issuer, we are exempt
from the rules of the Exchange Act prescribing the furnishing and content of proxy statements to shareholders under the federal proxy
rules contained in Sections 14(a), (b) and (c) of the Exchange Act, and our “insiders” are exempt from the reporting
and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. The SEC maintains an Internet site that contains
reports, proxy, information statements and other information regarding issuers at http://www.sec.gov. Copies of certain information filed
by us with the SEC are also available on our website at http://www.biodexapharma.com. Our website is not a part of this prospectus and
is not incorporated by reference in this prospectus.

This prospectus is part of
a registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance
with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information
on us and our consolidated subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed
as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified
by reference to these filings. You should review the complete document to evaluate these statements. You can obtain a copy of the registration
statement